id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S7981 R25293 |
Coste (Phenobarbital) (Controls exposed to Lamotrigine, sick), 2020 | Death (Mean follow up 3-4 years) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No Controls: mixed indications |
1.77 [0.10;30.62] C excluded (control group) |
0/84 9/2,813 | 9 | 84 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S7809 R25294 |
Coste (Phenobarbital) (Controls unexposed, NOS), 2020 | Death (Mean follow up 3-4 years) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 2.18 [0.13;35.07] C | 0/84 4,695/1,710,441 | 4,695 | 84 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S5526 R19255 |
Van der Pol (Phenobarbital) (Controls unexposed, disease free), 1991 | Death (from 6 to 13 years) | throughout pregnancy | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
4.84 [0.09;255.68] C excluded (control group) |
0/13 0/61 | 0 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6824 R19306 |
Van der Pol (Phenobarbital) (Controls unexposed, sick), 1991 | Death (from 6 to 13 years) | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 0.60 [0.02;15.86] C | 0/13 1/24 | 1 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 2 studies | 1.27 [0.15;10.56] | 4,696 | 97 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Phenobarbital) (Controls unexposed, NOS; 2: Phenobarbital) (Controls unexposed, sick;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 5526, 7981